Welcome to the UPF Digital Repository

Browsing Articles (Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)) by Author "Valderrama, Begoña P."

Browsing Articles (Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)) by Author "Valderrama, Begoña P."

Sort by: Order: Results:

  • Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma
    Font, Albert; Ruiz de Porras, Vicenç; Valderrama, Begoña P.; Ramirez, Jose Luis; Nonell Mazelón, Lara; Virizuela, José Antonio; Anido, Urbano; González-Del-Alba, Aránzazu; Lainez, Nuria; Llorente, Maria Del Mar; Jiménez, Natalia; Mellado, Begoña; García-Donas, Jesús; Bellmunt Molins, Joaquim, 1959- (MDPI, 2021)
    In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care in advanced urothelial cell carcinoma (aUCC) patients who did not progress after ...
  • Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
    de Jong, Joep J.; Valderrama, Begoña P.; Perera Bel, Júlia; Juanpere, Nuria; Cejas, Paloma; Long, Henry; Albà Soler, Mar; Gibb, Ewan A.; Bellmunt Molins, Joaquim, 1959- (Nature Research, 2022)
    Background: molecular subtyping of bladder cancer has revealed luminal tumors generally have a more favourable prognosis. However, some aggressive forms of variant histology, including micropapillary, are often classified ...
  • Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
    Bellmunt Molins, Joaquim, 1959-; Valderrama, Begoña P.; Puente, Javier; Grande, Enrique; Bolós, M. Victoria; Lainez, Nuria; Vázquez, Sergio; Maroto, Pablo; Climent, Miguel Ángel; Garcia del Muro, Xavier; Arranz, José Ángel; Durán, Ignacio (Elsevier, 2022)
    Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates ...
  • Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
    Pal, Sumanta; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt Molins, Joaquim, 1959-; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth P.; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begoña P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak (Future Medicine, 2022)
    PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk ...

Search DSpace


Advanced Search

Browse

My Account

Compliant to Partaking